Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBP-9414 for prevention of necrotizing enterocolitis in preterm infants
MOH_2020-01-29_008667Phase 3Recruiting
- Sponsor
- Infant Bacterial Therapeutics
- Start
- Nov 2018
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in necrotizing enterocolitis (NEC) comparing IBP-9414 with Placebo (2 arms). Started Nov 2018; status: recruiting.
02
Drugs
IBP-9414
03
Conditions
necrotizing enterocolitis (NEC)
Beyond the preview
Go deeper on MOH_2020-01-29_008667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-01-29_008667.